Document is current
Any future updates will be listed below
-
Authors
Wise, Michelle R. https://orcid.org/0000-0001-9194-9585
MacDonald, E. Jane
Knowles, Alison
Talbot, Sally
Shankar, Stephanie
Gibbons, Brittany
Lawton, Bev
Parag, Varsha
Baker, Ashleigh O’Mara
Amjad, Sophia
-
Funding
Funding for this research was provided by:
Health Research Council of New Zealand (22/713/A)
- License Information
-
More Information
Article History
Received: 4 October 2024
Accepted: 3 August 2025
First Online: 25 August 2025
Ethics approval and consent to participate
: This trial received ethics approval through the Health and Disability Ethics Committee (HDEC) New Zealand full review pathway (Northern B Health and Disability Ethics Committee) granted on 15 June 2023 (Reference: 2023 FULL 13189). Protocol amendment was granted on 15 January 2024. Progress reports are provided regularly to HDEC. Written, informed consent to participate will be obtained from all participants.
: The consent form given to participants can be provided on request to the PI.
: AK reports a conflict of interest as a director and shareholder of Istar Ltd. (registered charity CC20298). Istar Ltd. imports both Mifegyne (mifepristone) and CheckToP (low sensitivity urine pregnancy test). AK receives a nominal annual director’s fee from Istar Ltd. but does not receive any other dividends from the charity.The remaining investigators declare no conflict of financial or other competing interest.
